Vinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The Readout ...

The FDA proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be ...

Most of the infant formula in the U.S. is safe, but experts and health officials say regulators can take steps to make the ...

WASHINGTON — The Trump administration has dropped its nomination of Casey Means to be the next surgeon general, opting ...

The likelihood of snagging NIH grants has plunged to historic lows, forcing academic researchers to resort to a variety of ...

A new tool, OBSCORE, is meant to better define who's at risk for obesity complications, going beyond BMI to include family ...

J. Craig Venter, the scientist whose relentless ambition helped turn genetics from an artisanal trade into an industrialized ...

FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of ...

Elevance Health is blocking the deposition of Peter Haytaian, an outgoing executive who previously oversaw the health insurer ...

At the hearing, the judge heard from mothers who lost sons to overdose, a teenager born into withdrawal, and people who spent ...

Katherine Szarama, who joined the FDA last year to serve as Vinay Prasad’s deputy, will now fill his shoes at CBER.

For the first time, FDA regulators will be able to see what’s happening in a clinical trial, looking at endpoints in the ...